Ezubere iche ọgwụ maka ọgwụgwọ nke myelofibrosis: Ruxolitinib

A na-akpọ Myelofibrosis (MF) dị ka myelofibrosis.Ọ bụkwa ọrịa na-adịghị ahụkebe.Na ihe kpatara ya pathogenesis amaghị.Ngosipụta ụlọ ọgwụ a na-ahụkarị bụ mkpụrụ ndụ ọbara uhie na-eto eto na anaemia granulocytic na-eto eto nwere ọnụ ọgụgụ dị elu nke anya mmiri na-adaba mkpụrụ ndụ ọbara uhie.Ọchịchọ ụmị ọkpụkpụ na-egosipụtakarị agụụ nkụ, na splin na-abawanye nke ọma na ogo osteosclerosis dị iche iche.
Myelofibrosis nke mbụ (PMF) bụ ọrịa clonal myeloproliferative (MPD) nke mkpụrụ ndụ hematopoietic.Ọgwụgwọ nke myelofibrosis bụ isi na-akwado, gụnyere mmịnye ọbara.Enwere ike inye hydroxyurea maka thrombocytosis.Enwere ike ịhụ ndị ọrịa nwere obere ihe ize ndụ na-enweghị ọgwụgwọ.
A na-eme nchọpụta abụọ nke usoro III (STUDY1 na 2) na ndị ọrịa nwere MF (isi MF, post-geniculocytosis MF, ma ọ bụ post-primary thrombocythemia MF).N'ime ọmụmụ abụọ ahụ, ndị ọrịa debanyere aha nwere splenomegaly nwere ike ịchafụ ma ọ dịkarịa ala 5 cm n'okpuru oghere ọgịrịga ahụ ma nọrọkwa n'ogo (2 ihe prognostic) ma ọ bụ ihe egwu dị elu (3 ma ọ bụ karịa ihe prognostic) dị ka International Working Group consensus njirisi (IWG).
Usoro izizi nke ruxolitinib dabere na ọnụọgụ platelet.15 mg ugboro abụọ kwa ụbọchị maka ndị ọrịa nwere ọnụ ọgụgụ platelet dị n'etiti 100 na 200 x 10^9/L na 20 mg ugboro abụọ kwa ụbọchị maka ndị ọrịa nwere platelet karịrị 200 x 10^9/L.
A na-enye usoro onunu n'otu n'otu dabere na nnabata na ịdị irè maka ndị ọrịa nwere ọnụ ọgụgụ platelet n'etiti 100 na 125 x 10^9 / L, yana oke dose nke 20 mg ugboro abụọ kwa ụbọchị;maka ndị ọrịa nwere platelet ọnụ ọgụgụ n'etiti 75 na 100 x 10^9 / L, 10 mg ugboro abụọ kwa ụbọchị;na ndị ọrịa nwere platelet na-agụta n'etiti 50 na ihe na-erughị ma ọ bụ hà 75 x 10^9 / L, ugboro abụọ kwa ụbọchị na 5mg oge ọ bụla.
Ruxolitinibbụ ọnụ JAK1 na JAK2 tyrosine kinase inhibitor kwadoro na European Union na August 2012 maka ọgwụgwọ nke etiti ma ọ bụ nnukwu ihe ize ndụ myelofibrosis, gụnyere myelofibrosis bụ isi, post-geniculocytosis myelofibrosis na post-primary thrombocythemia myelofibrosis.Ugbu a, ruxolitinib Jakavi kwadoro na mba 50 n'ụwa nile, gụnyere European Union, Canada na ọtụtụ mba Asia, Latin na South America.


Oge nzipu: Jan-11-2022